GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
CRANBURY, N.J., Oct. 25, 2017 -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Wednesday, November 8, 2017 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2017.
The call will be hosted by John F. Crowley, Chairman and Chief Executive Officer. He will be joined on the call by additional members of the Amicus management team. Interested participants and investors may access the conference call by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international), conference ID: 5995789.
A live audio webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/, and will be archived for 30 days. Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register, download, and install any necessary software.
A telephonic replay of the call will be available for seven days beginning at 11:30 a.m. ET on November 8, 2017. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); conference ID: 5995789.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a global biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.
CONTACTS:
Investors/Media:
Amicus Therapeutics
Sara Pellegrino, IRC
Senior Director, Investor Relations
[email protected]
(609) 662-5044
Media:
W2O Group
Jennifer Paganelli
Media Relations
[email protected]
(347) 658-8290
FOLD–G
